Ascorbic acid combined with ibuprofen in hypoxic ischemic encephalopathy: a randomized controlled trial.

Area of Science:

• Neonatal neurology
• Perinatal medicine
• Biochemistry

Background:

• Hypoxic ischemic encephalopathy (HIE) in neonates is linked to free oxygen radicals and inflammatory cytokines.
• Effective treatments are crucial to mitigate brain injury and improve neurodevelopmental outcomes in affected infants.

Purpose of the Study:

• To investigate if a combination of antioxidants (ascorbic acid) and anti-inflammatory agents (ibuprofen) could reduce brain injury in HIE.
• To determine if this combined therapy improves neurodevelopmental outcomes in term infants treated immediately after birth.

Main Methods:

• A prospective, randomized, double-blinded controlled trial involving 60 asphyxiated term infants.
• Infants received either intravenous ascorbic acid and oral ibuprofen or a placebo for 3 days.
• Cytokine levels were measured, and neurological/developmental assessments were conducted at 6 months.

Main Results:

• No significant differences were observed between the intervention and control groups in HIE severity, mortality, neurological abnormalities, or developmental delay.
• Serum IL-1 beta and IL-6 concentrations correlated with HIE severity, and IL-6 correlated with 6-month neurodevelopmental outcomes.
• No complications were attributed to the ascorbic acid and ibuprofen intervention.

Conclusions:

• Early administration of ascorbic acid and ibuprofen did not alter outcomes for infants experiencing perinatal asphyxia.
• The ineffectiveness may be due to inadequate dosing, route of administration, or the involvement of other potent mediators in HIE brain injury.